Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
British Journal of Haematology|September 10, 2016
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective studyPhilip A Thompson, Vincent Lévy, Constantine S Tam, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Blood|November 17, 2021
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S Davids, Kerry A Rogers, Svitlana Tyekucheva, et al.
Blood Advances|March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
British Journal of Haematology|March 16, 2017
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survivalPhilip A Thompson, Francesco Stingo, Michael J Keating, et al.
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.
British Journal of Haematology|November 23, 2017
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabPreetesh Jain, Graciela M Nogueras González, Rashmi Kanagal-Shamanna, et al.
Pageof 7